164513-48-8Relevant academic research and scientific papers
ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS
-
Paragraph 0050, (2013/09/12)
Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.
ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS
-
Page/Page column 16-17, (2012/08/08)
Provided are compounds, and salts thereof, of formula (I): wherein (A) is R1 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl, or a group of the formula -C(O)-R12, where R12 may be C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl; R2 and R3 are independently hydrogen, C1-C5 alkyl, C1-C5 alkoxy, halogen, C1-C5 haloalkyl, or C1-C5 haloalkoxy; R4 and R5 are independently hydrogen, C1-C5 alkyl, or -(C1-C5 alkyl)phenyl; R6 is hydrogen, hydroxy, or is absent; R7 is hydrogen; R8 and R9 are independently hydrogen or methyl; R10 is hydrogen; R11 is hydrogen or C1-C5 alkyl; or R7 and R10 combine to form -CH2- or -(CH2)2-; or R8 and R9 combine to form a cyclopropyl group with the carbon to which they are attached; or R10 and R11 combine to form -CH2- or -(CH2)3-. Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.
ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS
-
Page/Page column 16-17, (2012/08/08)
Provided are analgesic compounds, and salts thereof, of formula: ( I ) wherein A is: ( A ) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.
INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
Page/Page column 107-108, (2012/06/16)
The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activato
INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
Page/Page column 48, (2012/12/13)
The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Asymmetric synthesis of chiral 9,10-dihydrophenanthrenes using Pd-catalyzed asymmetric intramolecular Friedel-Crafts allylic alkylation of phenols
Suzuki, Yuta,Nemoto, Tetsuhiro,Kakugawa, Kazumi,Hamajima, Akinari,Hamada, Yasumasa
supporting information; experimental part, p. 2350 - 2353 (2012/06/29)
We developed a novel asymmetric synthetic method for multisubstituted 9,10-dihydrophenanthrenes based on the Pd-catalyzed asymmetric intramolecular Friedel-Crafts allylic alkylation of phenols, which produces 10-vinyl or 10-isopropenyl chiral 9,10-dihydro
OXADIAZOLIDINEDIONE COMPOUND
-
Page/Page column 32, (2009/01/24)
[Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.
